Gross C R, Limwattananon C, Matthees B, Zehrer J L, Savik K
Academic Health Center, University of Minnesota, Minneapolis 55455, USA.
Transplantation. 2000 Dec 27;70(12):1736-46. doi: 10.1097/00007890-200012270-00013.
Simultaneous pancreas/kidney transplant (SPK) is an effective therapy that enables people with insulin-dependent diabetes mellitus (IDDM) and renal failure to maintain a more normal lifestyle, without the burdens of dialysis and insulin therapy. However, SPK has been viewed as a higher cost and higher risk procedure than kidney transplant, and it is unclear if SPK offers better health and quality of life (QOL) outcomes than insulin therapy plus kidney transplant alone (KTA). The purpose of this study is to determine which procedure affords better health and QOL outcomes.
This is a prospective observational study with assessments at pretransplant and 1 and 3 years posttransplant. Patients with IDDM and renal dysfunction who received either SPK or KTA from August 1990 to September 1993 at a university transplant center were enrolled. A convenience sample of patients with IDDM and complications not seeking transplants were enrolled during the same time interval. The main outcome measures were the SF-36 Short Form Health Survey and a Satisfaction with Diabetes Therapy Scale.
Most health status and QOL measures improved from baseline values within each transplant group. After adjustment for diabetes severity and other baseline variables, year 3 follow-up scores of the SPK cohort were better than those of the KTA cohort for several SF-36 scales: physical functioning (P=0.038); bodily pain (P=0.047), general health (P=0.014), and the physical component summary (P=0.003). SPK recipients also reported greater satisfaction with diabetes therapy (P=0.014) and perceived more benefits to secondary complications. The KTA patients, however, had higher adjusted scores for the role-emotional subscale (P=.037) and the mental component summary (P=.037). By year 3, the SPK cohort is at the 30th and 51st percentiles of the general adult US population in self-reported physical and mental health; the KTA cohort is at the 10th and 73rd percentile.
At follow-up, both SPK and KTA patients report better health and quality of life but SPK patients report greater improvements than KTA patients in physical health and in areas that are diabetes specific. Although the improved physical outcomes of SPK patients are consistent with perceived benefits to secondary complications, the mental health differences cannot be explained by the study data and warrant further study.
胰肾联合移植(SPK)是一种有效的治疗方法,能使胰岛素依赖型糖尿病(IDDM)和肾衰竭患者维持更正常的生活方式,摆脱透析和胰岛素治疗的负担。然而,与肾移植相比,SPK一直被视为成本更高、风险更大的手术,目前尚不清楚SPK在健康状况和生活质量(QOL)方面的结果是否优于单纯的胰岛素治疗加肾移植(KTA)。本研究的目的是确定哪种手术能带来更好的健康状况和生活质量结果。
这是一项前瞻性观察性研究,在移植前、移植后1年和3年进行评估。纳入1990年8月至1993年9月在某大学移植中心接受SPK或KTA的IDDM和肾功能不全患者。在同一时间间隔内纳入了一组方便样本,即患有IDDM和并发症但未寻求移植的患者。主要结局指标是SF-36简明健康调查和糖尿病治疗满意度量表。
每个移植组内,大多数健康状况和生活质量指标均较基线值有所改善。在对糖尿病严重程度和其他基线变量进行调整后,SPK队列在第3年随访时的几个SF-36量表得分优于KTA队列:身体功能(P=0.038);身体疼痛(P=0.047)、总体健康(P=0.014)和身体成分总结(P=0.003)。SPK受者对糖尿病治疗的满意度也更高(P=0.014),并认为继发性并发症的益处更大。然而,KTA患者在角色-情感分量表(P=0.037)和心理成分总结(P=0.037)方面的调整得分更高。到第3年时,SPK队列在自我报告的身心健康方面分别处于美国普通成年人的第30百分位和第51百分位;KTA队列则处于第10百分位和第73百分位。
在随访中,SPK和KTA患者的健康状况和生活质量均有所改善,但SPK患者在身体健康和糖尿病特定领域的改善程度高于KTA患者。虽然SPK患者身体状况的改善与继发性并发症的益处一致,但心理健康方面的差异无法用研究数据解释,值得进一步研究。